Because few substrates of BACE1 have been identified and BACE1 knockout mice were initially described as having no phenotype, chronic inhibition of BACE1 has been proposed as a potentially attractive therapy for Alzheimer's disease. Here, BACE1 is linked to early-onset autosomal dominant Alzheimer disease.